Provided by Tiger Trade Technology Pte. Ltd.

Incyte

124.75
+3.012.47%
Post-market: 124.74-0.0100-0.01%19:30 EDT
Volume:1.35M
Turnover:167.34M
Market Cap:25.29B
PE:15.89
High:124.96
Open:121.48
Low:121.48
Close:121.74
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:0.93
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.99
PE(LYR):19.46

Loading ...

Top Incyte Insiders Quietly Cash In On Major Stock Sale

TIPRANKS
·
Aug 05

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 05

Incyte EVP, Chief Scientific Officer Patrick Mayes Disposes of Shares Worth $5.32 Million

Reuters
·
Aug 05

Incyte price target raised to $137 from $121 at Mizuho

TIPRANKS
·
Aug 04

Mizuho Securities Remains a Buy on Incyte (INCY)

TIPRANKS
·
Aug 03

Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating

MT Newswires Live
·
Aug 03

Incyte Price Target Maintained with a $150.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 03

Incyte price target raised to $155 from $131 at Leerink

TIPRANKS
·
Aug 03

Incyte : Leerink Partners Raises Target Price to $155 from $131

THOMSON REUTERS
·
Aug 03

Incyte Corp. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 01

Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating

MT Newswires Live
·
Jul 31

Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Simply Wall St.
·
Jul 31

JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating

MT Newswires Live
·
Jul 30

Amneal Q2 Revenue Beats on Specialty Segment Growth

Reuters
·
Jul 30

Incyte Corp. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 30

Corcept Therapeutics Q2 Revenue Estimates, Raises 2026 Outlook

Reuters
·
Jul 30

Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says

MT Newswires Live
·
Jul 30

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Benzinga Earnings
·
Jul 29

Incyte Says Opzelura Cream Approved in EU to Treat Moderate Atopic Dermatitis

MT Newswires Live
·
Jul 29

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (GOVX), Incyte (INCY) and Altimmune (ALT)

TIPRANKS
·
Jul 29